Surrozen (NASDAQ:SRZN) Director Tim Kutzkey Acquires 2,562 Shares of Stock

Surrozen, Inc. (NASDAQ:SRZN) Director Tim Kutzkey acquired 2,562 shares of the stock in a transaction dated Friday, January 16th. The stock was bought at an average price of $20.00 per share, for a total transaction of $51,240.00. Following the purchase, the director owned 1,007,090 shares of the company’s stock, valued at $20,141,800. The trade was a 0.26% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Tim Kutzkey also recently made the following trade(s):

• On Tuesday, January 20th, Tim Kutzkey bought 18,052 shares of Surrozen stock. The shares were bought at an average price of $19.60 per share, with a total value of $353,819.20.
• On Thursday, January 15th, Tim Kutzkey purchased 11,893 shares of Surrozen stock. The stock was bought at an average price of $19.89 per share, for a total transaction of $236,551.77.
• On Wednesday, January 14th, Tim Kutzkey acquired 5,523 shares of Surrozen stock. The shares were bought at an average price of $19.99 per share, for a total transaction of $110,404.77.
• On Tuesday, January 13th, Tim Kutzkey acquired 12,470 shares of Surrozen stock. The shares were bought at an average cost of $19.80 per share, with a total value of $246,906.00.
• On Tuesday, January 6th, Tim Kutzkey bought 15,100 shares of Surrozen stock. The stock was bought at an average price of $19.89 per share, with a total value of $300,339.00.
• On Friday, December 5th, Tim Kutzkey bought 30,884 shares of Surrozen stock. The shares were purchased at an average cost of $19.54 per share, for a total transaction of $603,473.36.
• On Thursday, December 4th, Tim Kutzkey purchased 5,266 shares of Surrozen stock. The stock was purchased at an average cost of $17.35 per share, with a total value of $91,365.10.
• On Thursday, November 13th, Tim Kutzkey acquired 315,457 shares of Surrozen stock. The stock was purchased at an average price of $12.65 per share, with a total value of $3,990,531.05.

Surrozen Trading Down 10.1%

Shares of NASDAQ:SRZN opened at $17.98 on Wednesday. The firm has a market capitalization of $154.09 million, a PE ratio of -0.80 and a beta of 0.58. Surrozen, Inc. has a 1-year low of $5.90 and a 1-year high of $24.94. The business’s 50 day moving average is $18.98 and its 200-day moving average is $14.13.

Surrozen (NASDAQ:SRZN) last issued its earnings results on Friday, November 7th. The company reported ($3.61) EPS for the quarter, missing the consensus estimate of ($1.17) by ($2.44). Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%.The firm had revenue of $0.98 million during the quarter. On average, sell-side analysts predict that Surrozen, Inc. will post -8.49 EPS for the current year.

Key Surrozen News

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Director Tim Kutzkey completed three open‑market buys on Jan 15, Jan 16 and Jan 20 totaling 32,507 shares (~$641k at the reported prices). After the trades he directly owns ~1.02M shares (≈$19.9M value), a roughly 1–1.8% increase in his position; insider buys can be read as a vote of confidence by management. SEC filing — Kutzkey purchases
• Positive Sentiment: Major shareholder Group Gp Lp Column III mirrored the same purchases (Jan 15, 16, 20) for the same share counts and prices, increasing its stake to ~1.02M shares; large‑holder buying reinforces the insider signal and suggests continued institutional support. SEC filing — Group purchases
• Neutral Sentiment: The transactions were disclosed via routine SEC beneficial‑ownership filings; they do not change reported board composition or indicate corporate action (e.g., buyback or financing) beyond increased insider/holder positions. SEC website
• Negative Sentiment: Fundamentals remain a headwind: Surrozen reported a large Q3 earnings miss (EPS -$3.61 vs. -$1.17 expected) and minimal revenue, leaving the company with deep losses — this weak financial profile is the likely driver of downward pressure on the stock despite insider buying. MarketBeat — SRZN profile

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Braidwell LP acquired a new position in shares of Surrozen in the 2nd quarter worth approximately $1,252,000. Stempoint Capital LP boosted its stake in Surrozen by 185.1% in the second quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock worth $6,138,000 after purchasing an additional 445,713 shares in the last quarter. Stonepine Capital Management LLC grew its holdings in shares of Surrozen by 7.1% during the second quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock worth $2,736,000 after purchasing an additional 20,247 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Surrozen by 21.7% in the third quarter. Vanguard Group Inc. now owns 266,418 shares of the company’s stock valued at $3,433,000 after buying an additional 47,468 shares in the last quarter. Finally, Acuta Capital Partners LLC raised its holdings in shares of Surrozen by 5.0% in the third quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company’s stock valued at $2,299,000 after buying an additional 8,415 shares during the last quarter. Institutional investors own 66.57% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on SRZN shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research note on Wednesday, October 8th. Wall Street Zen upgraded Surrozen to a “sell” rating in a research note on Friday, November 28th. Finally, Lifesci Capital upgraded Surrozen to a “strong-buy” rating in a research report on Thursday, November 13th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Surrozen currently has an average rating of “Moderate Buy” and an average target price of $32.00.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.